Abstract
Patients and prescribers have recently been affected by interruptions to the supply of all formulations of the H2 antagonist ranitidine as a result of possible contamination with N‐nitrosodimethylamine. Here, Marco Motta and Mike Wilcock present the outcomes of their study evaluating the implications of these shortages for patients taking ranitidine from six GP practices in Cornwall.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
